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HIV-infected pregnant women with undetectable plasma HIV RNA concentrations at delivery pose a minimal risk of vertical
transmission. We studied the kinetics and the determinants of the virologic response to antiretroviral therapy in 117 consecutive
pregnancies.PatientswhoinitiatedtherapyduringpregnancyhadaVLdecreaseof2and2.5log10 after4and24weeks,respectively.
Therapeutic drug monitoring (TDM) of the protease inhibitors administered in doses recommended for nonpregnant adults
resulted in below-target concentrations in 29%, 35%, and 44% of 1st, 2nd, and 3rd trimester measurements, respectively, but
low drug concentrations did not correlate with virologic failure. Demographic characteristics, antiretroviral experience prior to
pregnancy, baseline VL, or use of speciﬁc antiretrovirals did not aﬀect the virologic response. Adherence to ≥95% of prescribed
doses and utilization of psychosocial services were associated with undetectable plasma HIV RNA at delivery. In conclusion, the
virologic responses of pregnant and nonpregnant adults share similar charactersitics.
Copyright © 2009 Adriana Weinberg et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Highly active antiretroviral (ARV) therapy (HAART) has
decreased HIV mother-to-child transmission (MTCT) to
<2% in the US and other countries where ARVs are readily
available [1–5]. This was achieved by suppressing maternal
HIV replication. In addition, scheduled Cesarean section
decreasestheriskofMTCT[1,6,7].Recentstudies,however,
suggest that Cesarean sections are not of signiﬁcant beneﬁt
when plasma HIV RNA is undetectable at delivery [2, 3].
SinceCesareansectionsincreasethecostofdeliveriesandrisk
of maternal complications, understanding the kinetics of the
virologic response to HAART during pregnancy may avoid
performing unnecessary Cesarean sections.
The dominant risk factor for MTCT is high maternal
viral load at delivery [8]. In nonpregnant individuals,
HAART generally decreases HIV plasma RNA and increases
CD4+ cells in parallel. This relationship has prompted the
u s eo fC D 4 +c o u n t sa sas u r r o g a t em e a s u r eo fr e s p o n s e
to therapy when plasma HIV RNA measurements are not
readily available. In pregnancy, however, this approach may
not be valid, as pregnancy is associated with lower CD4+
numbers. The kinetics of plasma HIV RNA and CD4+ cells
in response to HAART during pregnancy have been reported
in separate studies [9, 10]. The information provided by
these studies suggested that there may be a disconnect
between changes in CD4+ cells and plasma HIV RNA during
pregnancy. In this study, we analyzed these two parameters
in parallel.
Another important issue for prevention of MTCT
(PMTCT) is optimization of drug regimens during preg-
nancy, which typically include 2 nucleoside reverse tran-
scriptase inhibitors (NRTI) and a protease inhibitor (PI).
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studies during pregnancy showed that absorption and dis-
tribution of PIs diﬀer in 3rd trimester pregnant women
compared with nonpregnant adults, such that dose adjust-
ments may be warranted [11–13]. However, there is a lack
of information regarding PI pharmacokinetics during early
pregnancy.
To address these issues, we conducted a retrospective
chart review of pregnancies managed by the Children’s
Human Immunodeﬁciency Program (CHIP) in Denver. In
August 1997, CHIP became the reference center for the
care of HIV-infected pregnant women in Colorado and
neighboring states. These women come from a relatively
broad patient population that is highly representative of the
HIV epidemic in the Southwestern US.
2. Patientsand Methods
2.1. CHIP PMTCT Program. Patients were cared for by
a multidisciplinary team, comprising specialists in adult
and pediatric infectious diseases, obstetrics and maternal-
fetal medicine, nursing, social work, mental health, and
nutrition. Basic HIV-speciﬁc treatment consisted of ≥3
ARV including ≥2 classes of ARV. HIV genotype was
determined before treatment initiation in patients with
plasma HIV RNA ≥1000copies/mL. Adherence was facili-
tated by distributing pill boxes, watches, and pagers, oﬃce
counseling or home visits, and direct observed therapy.
PlasmaHIVRNAandCD4+cellsweremeasuredat2–6week
intervals.
PI plasma concentrations were assessed using high-
pressure liquid chromatography assays performed at the
National Jewish Hospital pharmacology laboratory, certiﬁed
by the AIDS Clinical Trials Group and compliant with the
Clinical Laboratory Improvements Amendments. For TDM,
drugs were administered in clinic with or without food, as
indicated.Troughconcentrationswereobtainedimmediately
before the dose. Peak concentrations of lopinavir (LPV)
weremeasured4hoursafteradministrationofLPV/ritonavir
(LPVr) and of other PIs 2 hours after administration of the
drug.
Treatment was modiﬁed based on drug levels, virologic
response, safety, and tolerability. Centralized treatment
decisions were made by the physician in charge of the
maternal care of the PMTCT program in consultation with
the primary infectious diseases provider of the patient, if
diﬀerent from the PMTCT physician.
The HIV-speciﬁc obstetrical plan included intravenous
zidovudine (AZT) administration during delivery except for
patientsonstavudine, whocontinued their oralmedications.
Cesarean sections were scheduled at 38 weeks of gestation
for consenting patients with VL > 1000copies/mL at ≥34
weeks gestation, as indicated by other medical obstetrical
conditions or patients’ choice.
Infants were treated during the ﬁrst 6 weeks of life
with AZT. When the maternal VL at the last visit prior
to delivery was ≥5,000copies/mL or >1000copies/mL with
vaginaldelivery,theneonatereceived2additionaldrugsfrom
2 ARV classes for the ﬁrst 4 weeks of life.
2.2. Chart Review. This study was reviewed by the local
IRB and deemed exempt from IRB approval due to the
retrospective nature of the study and absence of disclosure of
anypersonalinformation.Pregnancieswithdeliverybetween
Aug. 1997 (inception of the CHIP PMTCT program) and
Dec. 2005 (initiation of chart review) were identiﬁed in the
CHIP database. Information was abstracted for pregnancies
with ≥16-week duration and ≥2 visits at CHIP, using study-
speciﬁc forms.
2.3. Statistical Analysis. Analyses assumed a two-sided test
of hypothesis with a 0.05 signiﬁcance level. Associations
between categorical variables were determined using Fisher’s
exact test. Wilcoxon rank-sum test was used for comparisons
of continuous variables between two groups. Changes in VL
and CD4+ T-cell counts were tested using a signed-rank test.
To determine the kinetics of the virologic response, log10
VL was modeled as smooth functions of time on treatment
using a natural cubic B-spline transformation on time [14].
This analysis was run in the SAS mixed procedure (SAS
Institute, Inc.) and the B-splines were calculated using the
ns( ) command in Splus v8.0 (Insightful Corp). A random
intercept was included in all models and a random slope was
modeled using natural cubic B-splines. Akaike’s Information
Criterion was used to determine the ﬁnal model [15]. We
allowed a maximum of 5 and 3 degrees of freedom (df) for
the ﬁxed and random eﬀect B-splines, respectively, and the
ﬁnal model included the maximum, resulting in the most
ﬂexible model. The same ﬂexible analysis was used to model
CD4+ T-cell counts over time. The ﬁnal model included 5
and 1df for the ﬁxed and random eﬀects, respectively.
As VL was measured using diﬀerent assays, the lower
limit of detection varied. Six limits exist in our data: <20,
20–50, <50, <200, 200–400, and <400. In preparation for the
B-spline analyses, we imputed plasma HIV RNA copies/mL
such that those with (a) <20 were set to 10, (b) 20–50 to 35,
(c) <50 to the mean of all values <50 (real and imputed),
(d) <200 to the mean of all values below 200 (real and
imputed), (e) 200–400 to 300, and (f) <400 to the mean of
all values <400 (real and imputed). The log10 transformation
was conducted after the imputation.
3. Results
3.1. Demographics and HIV Disease Characteristics of the
Study Population. Medical records were available for 117 of
123 pregnancies that met inclusion criteria. These involved
12 women with 2 pregnancies (Table 1). The median age at
delivery was 30 years. Thirty-one patients (30%) were black
and 41 (39%) were Hispanic. A third of patients most likely
acquired HIV in a foreign country.
The most common risk factor for HIV acquisition was
heterosexual intercourse, reported by 97 patients (92%).
In 70 patients (67%), the diagnosis of HIV infection was
established before pregnancy. Of the 35 patients diagnosed
with HIV during pregnancy, 11 (34%) were diagnosed
during the ﬁrst trimester, 16 (50%) during the second
trimester, and 5 (16%) during the third trimester.Infectious Diseases in Obstetrics and Gynecology 3
Table 1: Demographics and baseline characteristics of HIV infec-
tion.
Characteristic N or Median (% or IQR)
Patients 105
One pregnancy with CHIP 93 (89)
Two pregnancies with CHIP 12 (11)
Maternal age at delivery 30 (26, 34)
Race
White 72 (68.6)
Black 31 (29.5)
Other 2 (1.9)
Ethnicity
Hispanic 41 (39)
Not Hispanic 64 (61)
Country of origin
African country∗ 15 (14)
Mexico 17 (16)
USA 66 (63)
Other 4 (4)
Unknown 3 (3)
HIV risk factors†
IV drug use 12 (11)
Heterosexual sex 97 (92)
Transfusion 5 (5)
HIV diagnosis
Prior to ﬁrst pregnancy at CHIP 70 (67)
During pregnancy 35 (33)
ARV experience
Naive 51 (44)
Experienced on therapy at the
o n s e to fp r e g n a n c y 29 (25)
Experienced oﬀ therapy at the
o n s e to fp r e g n a n c y 30 (26)
Unknown 7 (5)
Plasma HIV RNA at ﬁrst visit 109 pregnancies
Median (range) 2657 (225, 16700)
>400copies/mL 78 (72)
CD4+ count at ﬁrst visit 108 pregnancies
Median (range) 450 (269, 628)
<200cells/µL 13 (12%)
∗Includes Ethiopia, Liberia, Nigeria, Kenya, and Somalia.
†Nine patients have more than one risk factor.
At the ﬁrst pregnancy visit, the median VL was
2657copies/mL including 78 (72%) with >400copies/mL.
ThemedianCD4+T-cells was 450cells/µL;13women(12%)
had <200cells/µL. In 51 pregnancies (44%), the women were
ARV na¨ ıve and in 59 (50%) ARV experienced, including 29
patients who became pregnant on therapy.
3.2. Pregnancy Outcome. Median gestational age at delivery
was 38 weeks (interquartile range (IQR) = 37–40 weeks).
Table 2:AdherencetothelastARVregimenusedduringpregnancy.
ARV regimen N with ≥95% adherence/N total (%)
Any regimen 36/44 (82)
≥3-drug with PI 25/28 (89)
≥3-drug with NNRTI 3/5 (60)
≥3-drug with PI and
NNRTI 3/5 (60)
NRTI only 5/6 (83)
Thirty-six women (31%) delivered by scheduled Cesarean
section. The 114 single and 3 twin pregnancies resulted in,
117 infants without HIV infection, 1 fetal demise, 1 stillbirth
and 1 neonate who died of sepsis at 1 day of life. Of the 117
neonates who lived >1 day, 98 (84%) received AZT and 19
(16%) HAART. These infants were not infected with HIV.
TheincidenceofMTCTwas0witha95%conﬁdenceinterval
= 0% to 3%.
3.3. ARV Utilization during Pregnancy. At delivery, 106/114
(94%) pregnant women were on HAART (≥3d ru gsf r o m≥2
classes); 7 women (4%), who did not tolerate PIs or NNRTIs,
were on 2 or 3 NRTIs; and 1 woman, who delivered shortly
after referral precluding a change in therapy, was on AZT
monotherapy.ThemostcommondrugsatdeliverywereAZT
(N = 89), lamivudine (N = 108), stavudine (N = 22),
nevirapine (NVP; N = 19), nelﬁnavir (NFV; N = 55), and
LPVr (N = 25).
The median duration of continuous therapy up to
delivery was 22 weeks (IQR of 15 to 35 weeks). Among 84
women who started ARV during pregnancy after being oﬀ
therapy for several months or never being on therapy, the
median duration of therapy during pregnancy was 20 weeks
(IQRof11to25weeks).Ofthese,77(92%)receivedARVfor
≥4w e e k sa n d6 1( 7 3 % )f o r≥12 weeks.
3.4. Adherence. Adherence was measured by pill counts,
pharmacy reﬁll histories, MEMS caps, and detailed inter-
views in 44 pregnancies. Of these, 36 women (82%) took
≥95% doses of the prescribed medication, 7 (16%) took
50% doses–95%, and 1 took <50% doses. The analysis of
adherence by ARV regimen (Table 2) did not reveal any
diﬀerences across regimens.
3.5. Psychosocial Support. This was provided in 76 of 117
pregnancies. A median of 7 support interventions per
pregnancy took place (IQR = 4 to 13). These included case
management visits (N = 59), referrals to housing agencies
(N = 31)andpeeradvocacygroups(N = 30),food(N = 59)
and ﬁnancial (N = 56) assistance, and psychoeducational
group activities (N = 37).
3.6.VirologicResponsetoARVduringPregnancy. Forallstudy
participants, the median VL at delivery was 51copies/mL
(IQR < 20 to 292; N = 95), which represented a signiﬁcant
decrease compared with the ﬁrst pregnancy visit median of
2657copies/mL (P<. 0001). At the last visit before delivery,4 Infectious Diseases in Obstetrics and Gynecology
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Figure 1: Kinetics of the plasma HIV RNA in pregnant women
on HAART. Data were derived from 76 pregnant women who
initiated or reinitiated HAART during pregnancy. 0 weeks indicates
the beginning of therapy. Grey lines represent individual plasma
HIV RNA trajectories. The black line represents the population
curve generated by the mixed-model analysis. The predictions of
the model were conﬁrmed by additional analyses which showed
that at 4 weeks of HAART, 42% of mothers had <100 HIV RNA
copies/mL of plasma; at 12 weeks, 42% had <50copies/mL; and at
24weeks,56%had<50copies/mL.However,itshouldbenotedthat
the model’s estimated rise between 5 and 7 weeks is likely not real.
80 women (82%) had plasma HIV RNA <400copies/mL and
53 women (56%) had < 50 HIV RNA copies/mL.
To determine the kinetics of the virologic response to
HAART during pregnancy, we applied a mixed-model analy-
sis to data from 76 of 84 patients who initiated or reinitiated
HAART during pregnancy and had multiple tests during
pregnancy (Figure 1). The model, which uses all available
data to estimate the mean VL trajectory over time, estimated
that after 4 weeks of HAART the log10 VL decreased
by ∼2 logs from baseline to a back-transformed mean
<100copies/mL. Both at 12 and 24 weeks of HAART, the
estimated back-transformed mean VL was <50copies/mL.
We veriﬁed the predictions made by the model by calculating
the proportions of subjects with VL < 100copies/mL at 4
weeks and <50copies/mL at 12 and 24 weeks of HAART. Of
39 women with VL measurements at 4 weeks of HAART,
15 (42%) had <100copies/mL; at 12 weeks of HAART, 11
of 26 women (42%) had <50copies/mL; and at 24 weeks of
HAART, 9 of 16 women (56%) had <50copies/mL. These
data conﬁrmed the predictions of the model.
3.7. Immunologic Response to ARV during Pregnancy. At
delivery, the median CD4+ T-cell number was 540cells/µL
(IQR of 416 to 678; N = 92): 92% of values >200cells/µL.
The median CD4+ T-cell increase between ﬁrst pregnancy
visit and delivery was 88cells/µL( P<. 0001 by signed-rank
test; N = 92).
Inthemixed-modelanalysisusedtoelucidatethekinetics
of CD4+ T-cells during pregnancy, we set the reference time
at delivery to take into account the upward eﬀect of ARV and
the downward eﬀect of pregnancy on the CD4+ T-cells. The
model indicated that the CD4+ T-cells started to increase
at 6 weeks prior to delivery and peaked at approximately
8 weeks after delivery in all subjects (Figure 2(a)) and in
those who initiated or reinitiated HAART during pregnancy
(Figure 2(b)). Among 54 women with postpartum data,
there were no appreciable diﬀerences in postpartum CD4+
T-cell numbers of 36 women who continued therapy for ≥12
weeks, compared with those of 18 women who discontinued
therapy immediately after delivery. An additional mixed-
model analysis allowed for separate CD4+ T-cell trajectories
postdelivery for the 18 women who discontinued therapy
immediately after delivery and the 36 women who continued
therapyfor≥12weeks.Fromthismodel,theestimatedCD4+
T-cell count at 12 weeks postpartum was 763 and 679, for
women who stopped therapy and continued therapy for ≥12
weeks, respectively, a diﬀerence of 84 (P = .29).
3.8. PI Plasma Concentrations during Pregnancy. Thirty-
two pregnant women had ≥1 PI TDM for a total of 92
measurements. TDM was performed at a median of 5.5
weeks after initiation or change in therapy (IQR of 3.5
to 30 weeks). Eighty-two TDM assays were performed in
women taking PI doses recommended for nonpregnant
adults (regular) and 10 in women taking increased doses.
Table 3 depicts the TDM results from women on regular
PI doses. There were 7 measurements in the 1st trimester. Of
these, 4 (57%) were within the targeted range (normal), 2
(29%) were low, and 1 (14%) was high. The 57 TDM assays
from the second trimester included 34 (60%) normal, 20
(35%)low,and3(5%)highresults.The18TDMassaysfrom
the 3rd trimester included 9 (50%) normal, 8 (44%) low,
and 1 (6%) high results. Across all gestational ages, 57% of
the TDM results were normal, 37% low and 6% high. The
distributionofTDMresultsdidnotsigniﬁcantlydiﬀeracross
trimesters (Fisher’s exact test, P = .70).
The analysis of the plasma concentrations achieved by
the most commonly used PI in this study, LPVr, NFV, and
saquinavir (SAQr), showed that 75% of all LPV measure-
m e n t sw e r en o r m a la n d2 5 %w e r el o wa c r o s sa l lt r i m e s t e r s ;
20% to 59% of the NFV levels were normal with a trend of
decreasing concentrations from 1st to 3rd trimester; and 30
to 50% of SAQ concentrations were normal.
There were 10 PI TDM results during the 2nd or 3rd
trimester in women who received increased PI doses (6
received LPVr 533/133mg bid and 3 NFV 1500mg bid). Of
these, 3 measurements (30%) were below target.
3.9. Factors That Aﬀected Virologic Response to Therapy
during Pregnancy. To evaluate potential diﬀerences between
HAART regimens with respect to VL decay during preg-
nancy, the mixed-model analysis of log10 VL described above
(Virologic response to therapy) was used to compare NFV-Infectious Diseases in Obstetrics and Gynecology 5
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Figure 2: Kinetics of CD4+ counts in HIV-infected pregnant women on combination ARV. (a) Data were derived from 100 pregnant with
available data who started therapy before or during pregnancy. (b) Data were derived from 76 pregnant women who started therapy during
pregnancy after being oﬀ therapy for several months or never being on therapy. Time 0 indicates delivery. Grey lines represent individual
CD4+ trajectories. The black line represents the population curve generated by the mixed-model analysis.
Table 3: Distribution of therapeutic drug monitoring results of
protease inhibitors during pregnancy.
All LPVr NFV SAQr IDVr RTV
1 s t t r i m e s t e r 742 1 0 0
Low 2 (29) 1 (25) 1 0 0 0
Normal 4 (57) 3 (75) 1 0 0 0
High 1 (14) 0 0 1 0 0
2nd trimester 57 28 17 10 0 2
Low 20 (35) 7 (25) 6 (35) 5 (50) 0 2
Normal 34 (60) 21 (75) 10 (59) 3 (30) 0 0
High 3 (5) 0 1 (6) 2 (20) 0 0
3rd trimester 18 5 5 4 2 2
Low 8 (44) 1 (20) 4 (80) 2 (50) 1 0
Normal 9 (50) 4 (75) 1 (20) 2 (50) 0 2
High 1 (6) 0 0 0 1 0
Numbers (%) represent pregnant women taking PI doses recommended for
adults.
Abbreviations: IDVr = indinavir/ritonavir; LPVr = lopinavir/ritonavir; NFV
= nelﬁnavir; RTV = ritonavir; SAQr = saquinavir/ritonavir.
(N = 49) versus LPVr-containing HAART (N = 20).
Diﬀerences in estimated log10 VL between the regimens,
calculated as NFV estimate minus LPVr estimate, were 0.01
(P = .96), 0.44 (P = .10), 0.39 (P = .12), and 0.09 (P = .78)
at 4, 8, 12, and 24 weeks on treatment, respectively.
An analysis of the factors that could potentially aﬀect
the response to therapy deﬁned by undetectable VL at
delivery, including race, ethnicity, country of origin (as a
surrogate of HIV-1 clade), magnitude of VL before initiation
of therapy, ARV experience, HIV drug resistance (data
presented elsewhere) [16], adherence, TDM, and utilization
of psychosocial support services, was performed (Table 4).
The data revealed signiﬁcant associations only for adherence
(P = .006) and psychosocial support (P = .010).
4. Discussion
To determine what length of HAART administration during
pregnancy was needed to achieve undetectable VL, we
analyzedthekineticsofthevirologicresponseinwomenwho
started HAART during pregnancy. The time to undetectable
VL did not diﬀer from that previously reported in HIV-
infected nonpregnant adults [17, 18], with a majority of
pregnant women achieving VL < 50copies/mL after 12 to
24 weeks of therapy. The corollary of this observation is
that pregnant women who start HAART during or before
the 2nd trimester are likely to achieve VL < 50copies/mL
at delivery. In contrast, women starting HAART less than
4 weeks before the anticipated date of delivery are likely
candidates to scheduled Cesarean sections.6 Infectious Diseases in Obstetrics and Gynecology
Table 4: Relationship between virologic response to ARV during
pregnancy and selective factors that may aﬀect this response.
Factor N (%)
undetectable
N (%)
detectable
P value
Country of origin .16
US 39 (80) 10 (20)
Mexico 11 (79) 3 (21)
African country 15 (100) 0
HIV plasma RNA at
ﬁrst visit
≥50,000copies/mL 6 (75) 2 (25) .63
<50,000copies/mL 72 (83) 15 (17)
Prepregnancy ARV .27
Naive 33 (77) 10 (23)
Experienced 40 (87) 6 (13)
TDM .38
Performed 53 (79) 14 (21)
Not performed 25 (89) 3 (11)
Adherence .006
<50% 1 (100) 0
50% to 95% 3 (50) 3 (50)
>95% 29 (94) 2 (6)
Psychosocial support .01
Utilized 63 (89) 8 (11)
Not utilized 15 (63) 9 (37)
In our patient population, the rate of Cesarean section
was similar to that reported for other areas in the US
and lower than that reported in Europe, where the use of
scheduled Cesarean section is twice as common as in the
US [1, 19]. However, MTCT in this study was lower than
that documented in contemporaneous studies in the US
[4, 19] and similar to that reported in Europe [1, 3]. These
diﬀerences may be explained by the fact that 94% of HIV-
infected pregnant women in this study received HAART for
PMTCT, which is a higher proportion than the rate of 50%
to 70% documented in other studies [2–5]. Taken together,
these observations suggest that high uptake of HAART may
decreasetheneedofscheduledCesareansectionsforPMTCT
[2, 3] without compromising protection of the neonate
against HIV infection.
The analysis of the kinetics of CD4+ T-cells in pregnancy
revealed a delay in the response to HAART compared
with the kinetics of VL. In pregnancy, the most signiﬁcant
increases in CD4+ T-cell numbers occurred in the last 6
weeks of pregnancy and ﬁrst 6 weeks of postpartum. This
pattern was observed in women who started HAART before
or during pregnancy and was independent of continuing
HAART post-partum. This pattern is most likely due to
physiologic changes of pregnancy, including the increased
volume of distribution of white blood cells and/or hormonal
changes depressing CD4+ T-cells. The implication of this
observation is that a lack of increase of CD4+ T-cells in
pregnant women may not indicate virologic failure.
An important question in the care of HIV-infected preg-
nant women is whether there is an ARV regimen more likely
than others to rapidly decrease the VL in women diagnosed
with HIV late in pregnancy. We did not ﬁnd any signiﬁcant
diﬀerences in the kﬁnetics of VL as a function of the PI
used in HAART. Previous studies showed that nonpregnant
HIV-infected adults on NFV-containing regimens were less
likely to achieve or maintain viral suppression compared
with individuals receiving LPVr-containing regimens [20].
However,duringthelimiteddurationoftherapyforPMTCT,
this diﬀerence may not be relevant. These data suggest that
although HAART is critical in order to achieve a satisfactory
virologic response during pregnancy, the choice of PI has
secondary importance with respect to virologic response.
Patel et al. showed that NVP-based regimens are associated
with faster decay of VL compared with NFV-based regimens
[10].Inthisstudy,thenumberofwomenwhointitiatedNVP
during pregnancy was too low for a formal analysis. Further
studies using NNRTIs that do not carry the same high risk of
serious adverse events as NVP are warranted to determine
whether an NNRTI-based regimen may be advantageous
when therapy is initiated late in pregnancy.
With respect to plasma concentrations achieved by
various PIs during pregnancy, we found that LPVr levels
were below target in 20% to 25% of pregnant women on
adult recommended doses across all trimesters, whereas for
another PI, 35% to 80% of the levels were below target.
Others have shown that up to 72% of women on LPVr
do not reach target concentrations of LPV during the 3rd
trimester [11, 12, 21]. Acosta et al. found SAQ plasma levels
uniformly above target [22] during pregnancy, whereas in
our study 50% of subjects had levels below target. Our
ﬁndings on NFV plasma concentrations are in accordance
with those of Nellen et al. who also found that 51%
of pregnant women did not reach target concentrations
[23]. Diﬀerences in drug concentrations across studies may
be accounted by technical diﬀerences, eﬀects of race and
ethnicity on drug metabolism, and compliance with therapy.
A novel contribution of our study is to reveal that plasma
PI concentrations are often below target not only in the
last trimester of pregnancy but also earlier in pregnancy.
This suggests that other factors, in addition to the increased
volume of distribution of the drugs, may contribute to
this eﬀect. The practical implication of our ﬁndings is to
underscore the importance of performing TDM or other
pharmacokineticstudiesduringthe1stand2ndtrimestersof
pregnancy and also after each dose modiﬁcation, since 30%
of the pregnant women on increased PI doses had plasma
drug levels below target.
The use of TDM did not signiﬁcantly aﬀect the virologic
response to therapy in this study. Some studies in non-
pregnant HIV-infected adults showed improved virologic
response to PI-containing regimens in subjects whose doses
were adjusted based on TDM results [24–26], but one study
failed to show any beneﬁt [27]. This last study had a period
of followup of only 12 weeks. Likewise, it may be diﬃcult
to assess the beneﬁt of TDM in pregnancy due to the
limited duration of therapy. Nevertheless, it is reasonable to
assume that it would be undesirable to administer drugs atInfectious Diseases in Obstetrics and Gynecology 7
subtherapeutic levels to control a virus that has the ability to
quickly develop drug resistance mutations [28], particularly
ifARVcontinuestobeadministeredafterpregnancy.Further
studies are warranted to determine the eﬀect of TDM on the
development of resistance to ARV.
Among multiple factors that could potentially aﬀect
virologicresponsetotherapy,suppressionofviralreplication
atdeliverywaspositivelyassociatedwithadherence,conﬁrm-
ing previous observations [29]. We did not ﬁnd signiﬁcant
diﬀerences in adherence between patients receiving once
daily versus twice daily regimens or PI-containing versus
sparing regimens, which is a novel ﬁnding, perhaps speciﬁc
of pregnancy and has important implications for the clinical
practice. Overall, ≥95% adherence was recorded in 82% of
the women in this study, which is consistent with other
reports [30].
Utilization of psychosocial support services was signiﬁ-
cantly associated with virologic response to therapy during
pregnancy, which makes intuitive sense, but has not been
previously demonstrated in a formal analysis. Although
the association between utilization of psychosocial services
and virologic success may indicate that women who are
committed to medical treatment for PMTCT are also likely
to seek resources to improve other aspects of their lives, it
may also indicate that support services facilitate adherence
to therapy [30–32].
In summary, undetectable VL at delivery was associated
with lack of vertical transmission of HIV in this group
of women who predominantly delivered by vaginal route.
Undetectable VL was achieved as soon as 4 weeks after
initiation of HAART in 50% of the patients and at 12
weeks in the vast majority. Achieving undetectable VL at
delivery did not depend on the speciﬁc PIs or NNRTIs
included in the treatment regimen. Adherence, which was
important to reach undetectable VL at delivery, did not
vary with the drugs included in the treatment regimen,
either. The pattern that emerges is that critical factors
for PMTCT without high utilization of Cesarean sections
are initiating therapy ≥12 weeks prior to delivery with
ar e g i m e nt h a ti sw e l lt o l e r a t e da n dc o n d u c i v et o≥95%
adherence.
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